Name: DMF (Dimethyl Fumarate)
Brand: Selleck Chemicals
SKU: S2586
Rating: 5 (21 reviews)

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 100.00%

100.00

Dianas relacionadas	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Otros Nrf2 Inhibidores	Bardoxolone Methyl (RTA 402) ML385 TBHQ Sulforaphane Brusatol Oltipraz Bardoxolone (CDDO) 4-Octyl Itaconate (4-OI) KI696 Mangiferin

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular	144.13	Fórmula	C₆H₈O₄	Almacenamiento (Desde la fecha de recepción)	3 años-20°Cpolvo
Nº CAS	624-49-7	Descargar SDF		Almacenamiento de soluciones madre	1 año-80°Cen disolvente 1 mes-20°Cen disolvente
Sinónimos	BG-12			Smiles	COC(=O)C=CC(=O)OC

Solubilidad (Solubility)

In vitro
Lote:

DMSO : 29 mg/mL (201.2 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Ethanol : 29 mg/mL

Water : Insoluble

Calculadora de Molaridad

Masa	Concentración	Volumen	Peso molecular
=	×	×

Calculadora de Dilución Calculadora de Peso Molecular

In vivo Lote:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	1.000mg/ml (6.94mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	3.750mg/ml (26.02mM)	Taking the 1 mL working solution as an example, add 50 μL of 75 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10%DMSO 1 40%PEG300 2 5%Tween80 3 45%ddH2O Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	1.500mg/ml (10.41mM)	Taking the 1 mL working solution as an example, add 100 μL of 15 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10% DMSO 1 90% corn oil Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	4.200mg/ml (29.14mM)	Taking the 1 mL working solution as an example, add 100 μL of 42 mg/ml clear DMSO stock solution to 900 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

Dosis: mg/kg Peso promedio de los animales: g Volumen de dosificación por animal:μL Número de animales:

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH₂O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

In vitro	Dimethyl fumarate (DMF) causes short-lived oxidative stress, which leads to increased levels and nuclear localization of the transcription factor nuclear factor erythroid 2-related factor 2 and a subsequent increase in glutathione synthesis and recycling in neuronal cells. It inhibits dendritic cell (DC) maturation by reducing inflammatory cytokine production (IL-12 and IL-6) and the expression of MHC class II, CD80, and CD86. This compound impairs nuclear factor κB (NF-κB) signaling via reduced p65 nuclear translocalization and phosphorylation. It inhibits maturation of DCs and subsequently Th1 and Th17 cell differentiation by suppression of both NF-κB and ERK1/2-MSK1 signaling. DMF inhibits TNF-alpha-induced nuclear entry of NF-kappaB in rat heart endothelial cells (RHEC). As an immune modulator and inducer of the antioxidant response, it suppresses HIV replication and neurotoxin release. It also attenuates CCL2-induced monocyte chemotaxis, suggesting that this compound could decrease recruitment of activated monocytes to the CNS in response to inflammatory mediators.
In vivo	Dimethyl fumarate (DMF) inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. Its oral administration is shown to upregulate mRNA and protein levels of Nrf2 and Nrf2-regulated cytoprotective genes, attenuate 6-OHDA induced striatal oxidative stress and inflammation in C57BL/6 mice.
Referencias	[1] https://pubmed.ncbi.nlm.nih.gov/22769044/ [2] https://pubmed.ncbi.nlm.nih.gov/22733812/ [3] https://pubmed.ncbi.nlm.nih.gov/18405893/ [4] https://pubmed.ncbi.nlm.nih.gov/21976775/ [5] https://pubmed.ncbi.nlm.nih.gov/25449120/

Aplicaciones (Applications)

Métodos	Biomarcadores	Imágenes	PMID
Western blot	NRF2 / IRP2 / FBXL5 / FTH1 / FTL		28289076

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2026-03-19)

Número NCT	Reclutamiento	Condiciones	Patrocinador/Colaboradores	Fecha de inicio	Fases
NCT07483632	NOT_YET_RECRUITING	Relapsing Forms of Multiple Sclerosis	Biogen	2026-11-16	PHASE3
NCT07189325	RECRUITING	Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy	University Hospital, Montpellier	2026-06-15	PHASE3
NCT07548996	RECRUITING	Type 1 Diabetes Mellitus	Nanjing Medical University	2026-04-27	PHASE2; PHASE3
NCT07258394	RECRUITING	Type 1 Diabetes	Nanjing Medical University	2026-01-27	PHASE3
NCT04381936	RECRUITING	Pneumonia	University of Oxford	2020-03-19	PHASE3
NCT07776743	RECRUITING	Relapsing-remitting Multiple Sclerosis (RRMS)	Guangzhou Lupeng Pharmaceutical Company LTD.	2026-08	PHASE2

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

DMF (Dimethyl Fumarate) Nrf2 Activador

Peso molecular: 144.13